Subdiaphragmatic Hodgkin's disease: The University of Florida experience

International Journal of Radiation Oncology Biology Physics

Volumn 52, Issue 1, 2002, Pages 161-166

  Hull, Matthew C ^a   Price Mendenhall, Nancy ^a,b   Colgan, Mark E ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Dept of Radiation Oncology ^*  (United States)

Author keywords

Adverse effects of radiotherapy; Combined modality therapy; Hodgkin's disease; Radiotherapy; Results of treatment

Indexed keywords

CHEMOTHERAPY; DIAGNOSIS; DISEASES; IRRADIATION; MEDICAL IMAGING; PATIENT MONITORING;

NODULAR SCLEROSING;

ONCOLOGY;

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGE; AGED; ANUS CANCER; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HEART DISEASE; HODGKIN DISEASE; HUMAN; INGUINAL REGION; LUNG CANCER; LYMPH NODE IRRADIATION; LYMPHOCYTE COUNT; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RECURRENCE RISK; SCLEROSIS; SECOND CANCER; SPLEEN; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DIAPHRAGM; DISEASE-FREE SURVIVAL; FEMALE; FLORIDA; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; INGUINAL CANAL; MALE; MECHLORETHAMINE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; VINCRISTINE;

EID: 0036140375     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01813-2     Document Type: Article

References (29)

1. Infradiaphragmatic Hodgkin's disease
2. Management of supradiaphragmatic early-stage Hodgkin's disease
3. Stage I and II Hodgkin's disease presenting in infradiaphragmatic nodes
4. Hodgkin's disease stages I and II with infradiaphragmatic presentation; A rare and prognostically unfavorable combination
5. Subdiaphragmatic Hodgkin's disease; Laparotomy and treatment results in 49 patients
6. Infradiaphragmatic Hodgkin's disease, long term follow-up of rare presentation
7. Radiotherapy for early infradiaphragmatic Hodgkin's disease; The Australasian experience
8. Stage I and II subdiaphragmatic Hodgkin's disease
9. Treatment of subdiaphragmatic Hodgkin's disease; Is radiotherapy alone appropriate only for inguino-femoral presentations
10. Report of the Committee on Hodgkin's Disease Staging Classification
11. Nonparametric estimation from incomplete observations
12. Hodgkin's disease, stages I and II occurring below the diaphragm
13. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease
14. Hodgkin's disease; Complications of therapy and excess mortality
15. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography
16. Value of electron-beam computed tomography for the noninvasive detection of high-grade coronary-artery stenoses and occlusions
17. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease; An international collaborative study among cancer registries
18. Risk of second cancers after treatment for Hodgkin's disease
19. Second cancer after the treatment for Hodgkin's disease; A report from the International Database on Hodgkin's Disease
20. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease
21. Risk of second primary cancers after Hodgkin's disease by type of treatment; Analysis of 2846 patients in the British National Lymphoma Investigation
22. Second malignancies after treatment of Hodgkin's disease; The influence of treatment, follow-up time, and age
23. Second cancer risk following Hodgkin's disease; A 20-year follow-up study
24. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation; Relationships, host factors, histology and stage of Hodgkin's disease, and splenectomy
25. Diagnostic procedures and guidelines for the evaluation and follow-up of Hodgkin's disease
26. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease; Influence on patient management in a single institution
27. NCCN practice guidelines for Hodgkin's disease
28. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis